Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 17Thoracic 2Dermatologic 2Other solid neoplasm 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 89pembrolizumab 83Magnetic Resonance Spectroscopy 47Radiotherapy, Intensity-Modulated 41Specimen Handling 37Cetuximab 37Carboplatin 37Radiotherapy 36Nivolumab 29Paclitaxel 25Platinum 23Radiation 22Docetaxel 22Gemcitabine 21Biopsy 211,2-diaminocyclohexaneplatinum II citrate 21Surveys and Questionnaires 17Fluorouracil 14toripalimab 13Standard of Care 13Taxes 11Cyclophosphamide 10cemiplimab 9atezolizumab 9X-Rays 9Surgical Procedures, Operative 9Ipilimumab 9Immunoglobulin G 9Drug Therapy 9Capecitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brentuximab Vedotin × Head & Neck × 90 days × Clear all
NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Seagen Inc.

Phase 2 Completed
161 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡